Latest news with #AquestiveTherapeutics
Yahoo
21-05-2025
- Business
- Yahoo
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential
We recently published an article titled . Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article. Wall Street analysts believe AQST has a 245% upside potential over the next 12 months. A pharmacist showing a patient a green sublingual film formulation with buprenorphine and naloxone. Upside Potential: 245.96% Aquestive Therapeutics (NASDAQ:AQST) stands out as a dynamic pharmaceutical company that has carved a distinct niche in the field of drug delivery innovation. Founded in 2004 in Warren, New Jersey, the company specializes in developing and commercializing advanced drug delivery systems designed to improve both absorption and patient convenience. Its flagship PharmFilm technology represents a groundbreaking approach to medication administration. Thin, dissolvable films created through this technology can be used sublingually (under the tongue), buccally (inside the cheek), or lingually (on the tongue), offering an alternative to traditional tablets or injections. This innovation not only enhances ease of use but also ensures faster and more reliable delivery of active ingredients, making it particularly beneficial for patients with difficulty swallowing or those requiring rapid onset of treatment. Aquestive has leveraged its PharmFilm technology to build an impressive portfolio of FDA-approved treatments that address critical health conditions. Among its notable products are Libervant, designed to manage seizures; Sympazan, which provides relief for individuals with Lennox-Gastaut syndrome, a severe form of epilepsy; and Suboxone, a treatment aimed at combating opioid dependence. The company's unique ability to merge pharmaceutical expertise with convenience-centric solutions has enabled it to establish a robust patent portfolio. Aquestive's collaborations with leading pharmaceutical firms further cement its position in the global market, ensuring its innovative therapies reach a wider audience and bring meaningful improvements to patients' lives. Financially, Aquestive continues to demonstrate resilience and potential for growth. In the fourth quarter of 2024, the company reported revenues of $11.87 million, reflecting a year-over-year decline of 10.14%, but its full-year revenue of $55.2 million underscores steady progress in its proprietary PharmFilm technology. With secure cash reserves of $65.1 million, Aquestive is well-positioned to advance its drug pipeline and pursue ambitious research and development goals. Analysts remain optimistic about its prospects, forecasting a twelve-month average share price of $9.86, representing a remarkable upside potential of 245.96%. Aquestive Therapeutics is undoubtedly poised for significant advancements in the pharmaceutical industry. Overall, Aquestive Therapeutics, Inc. (NASDAQ:AQST) ranks 12th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of AQST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AQST and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Aquestive Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $8.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.14%. This compares to year-ago revenues of $12.05 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aquestive Therapeutics shares have lost about 21.6% since the beginning of the year versus the S&P 500's decline of -3.8%. While Aquestive Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aquestive Therapeutics: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $11.87 million in revenues for the coming quarter and -$0.65 on $49.55 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, CASI Pharmaceuticals Inc. (CASI), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of +14.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. CASI Pharmaceuticals Inc.'s revenues are expected to be $6.1 million, up 78.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report CASI Pharmaceuticals Inc. (CASI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
12-05-2025
- Business
- Washington Post
Aquestive Therapeutics: Q1 Earnings Snapshot
WARREN, N.J. — WARREN, N.J. — Aquestive Therapeutics Inc. (AQST) on Monday reported a loss of $22.9 million in its first quarter. On a per-share basis, the Warren, New Jersey-based company said it had a loss of 24 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share. The specialty pharmaceutical company posted revenue of $8.7 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $12.1 million. In the final minutes of trading on Monday, the company's shares hit $2.87. A year ago, they were trading at $3.09. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on AQST at
Globe and Mail
18-03-2025
- Health
- Globe and Mail
ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma
The Key Epilepsy Companies in the market include - Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others. DelveInsight's 'Epilepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast Some of the key facts of the Epilepsy Market Report: The Epilepsy market size was valued ~USD 9 billion in 2023 and is anticipated to grow with a significant CAGR of 7% during the study period (2020-2034) In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy. In November 2024, uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on developing treatments for severe medical conditions, has announced that the first patient has been administered AMT-260 in the GenTLE Phase I/IIa clinical trial for refractory mesial temporal lobe epilepsy (MTLE). In September 2024, Synergia Medical successfully implanted its neurostimulation technology in the first two patients participating in a study aimed at treating epilepsy. These procedures are part of a first-in-human trial being conducted at two locations in Belgium and one in Germany. The surgeries for the initial patients were performed earlier this month at the Belgian sites, according to the company. In 2023, the Epilepsy Treatment Market in the US was valued at around USD 4.3 billion, representing approximately 48% of the total market revenue across the 7MM. In 2023, the Epilepsy Treatment Market in the EU4 and the UK held a market share of approximately 29%. Among these countries, Germany had the largest market share, followed by France and the UK. These figures are expected to evolve during the forecast period. In 2023, the Epilepsy Treatment Market Size in Japan was estimated to be around USD 2.1 billion. In 2023, the total diagnosed prevalent cases of epilepsy in the 7MM were approximately 7 million, with an expected compound annual growth rate (CAGR) of 0.4% through 2034. In 2023, the US had around 3.3 million total diagnosed epilepsy cases, with 14% of them in children and 86% in adults. The total number of epilepsy cases is anticipated to rise by 2034. In 2023, the EU4 and the UK had approximately 1.3 million male cases and 1.5 million female cases of diagnosed epilepsy, with these figures expected to increase over the study period. In 2023, Germany reported the highest number of epilepsy cases among the EU4 and the UK, with approximately 735 thousand cases. Of these, nearly 74% were focal seizures, 18% were generalized seizures, and 8% were classified as other determined or undetermined epileptic seizures. In 2023, Japan had the second-highest number of diagnosed epilepsy cases among the 7MM, with approximately 890 thousand cases. These numbers are anticipated to change over the course of the study period. In Japan, drug-resistant epilepsy/refractory cases accounted for the highest number of epilepsy cases, with approximately 82 thousand in 2023, followed by photosensitivity and childhood absence epilepsy, each with 44 thousand cases. These figures are projected to change by 2034. The epilepsy market is expected to experience steady growth, with a compound annual growth rate (CAGR) of around 7% projected from 2024 to 2034. This growth across the 7MM will be fueled by the launch of new therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others. DelveInsight estimates that in 2023, there were around 7 million total diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% of the cases were in the US, 39% were in the EU4 and the UK, and 13% were in Japan. Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others The Epilepsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics. Epilepsy Overview Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases. Get a Free sample for the Epilepsy Market Report Epilepsy Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Epilepsy Epidemiology Segmentation: The Epilepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast Epilepsy Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Epilepsy Therapies and Key Companies Epilepsy Market Strengths Growing Focus On Providing Seizure-Free Life To Fuel Innovations. Growth in The Demand For Epileptic Seizures Treatment Epilepsy Market Opportunities Growing funding for R&D of epilepsy is also contributing as a factor for the market growth. Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market Scope of the Epilepsy Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. Epilepsy Market Report Introduction 2. Executive Summary for Epilepsy 3. SWOT analysis of Epilepsy 4. Epilepsy Patient Share (%) Overview at a Glance 5. Epilepsy Market Overview at a Glance 6. Epilepsy Disease Background and Overview 7. Epilepsy Epidemiology and Patient Population 8. Country-Specific Patient Population of Epilepsy 9. Epilepsy Current Treatment and Medical Practices 10. Epilepsy Unmet Needs 11. Epilepsy Emerging Therapies 12. Epilepsy Market Outlook 13. Country-Wise Epilepsy Market Analysis (2020–2034) 14. Epilepsy Market Access and Reimbursement of Therapies 15. Epilepsy Market Drivers 16. Epilepsy Market Barriers 17. Epilepsy Appendix 18. Epilepsy Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
08-03-2025
- Business
- Yahoo
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
Shareholders might have noticed that Aquestive Therapeutics, Inc. (NASDAQ:AQST) filed its annual result this time last week. The early response was not positive, with shares down 5.4% to US$2.65 in the past week. Revenues came in at US$58m, in line with expectations, while statutory losses per share were substantially higher than expected, at US$0.51 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. See our latest analysis for Aquestive Therapeutics After the latest results, the consensus from Aquestive Therapeutics' nine analysts is for revenues of US$49.6m in 2025, which would reflect a chunky 14% decline in revenue compared to the last year of performance. Per-share losses are expected to explode, reaching US$0.68 per share. Before this latest report, the consensus had been expecting revenues of US$53.0m and US$0.61 per share in losses. While this year's revenue estimates dropped there was also a considerable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock. The consensus price target fell 9.0% to US$9.86, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Aquestive Therapeutics analyst has a price target of US$15.00 per share, while the most pessimistic values it at US$4.75. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 14% annualised decline to the end of 2025. That is a notable change from historical growth of 1.5% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 8.5% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Aquestive Therapeutics is expected to lag the wider industry. The most important thing to take away is that the analysts increased their loss per share estimates for next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Aquestive Therapeutics going out to 2027, and you can see them free on our platform here. It is also worth noting that we have found 3 warning signs for Aquestive Therapeutics (2 can't be ignored!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
